Search Results | Clinical Cancer Research | American Association for Cancer Research

1-19 of 19

Sort by

Sort Order Select

Journal Articles

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

Clin Cancer Res (2022) 28 (5): 893–902.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-3194

Published: 03 March 2022

View article

Includes: Supplementary data

Journal Articles

Correction: KRAS Inhibitor Resistance in MET-Amplified KRAS^G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura, Toshiyuki Takehara, Ryoji Kato, Hitomi Sakai, Koji Haratani, Junko Tanizaki, Hisato Kawakami, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa

Clin Cancer Res (2022) 28 (2): 428.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-4240

Published: 19 January 2022

View article

Journal Articles

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Clin Cancer Res (2022) 28 (2): 390–403.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-3359

Published: 19 January 2022

View article

Journal Articles

KRAS Inhibitor Resistance in MET-Amplified KRAS^G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

Clin Cancer Res (2021) 27 (20): 5697–5707.

DOI: https://doi.org/10.1158/1078-0432.CCR-21-0856

Published: 01 October 2021

View article

Includes: Supplementary data

Journal Articles

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Clin Cancer Res (2018) 24 (11): 2653–2664.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-2852

Published: 31 May 2018

View article

Includes: Supplementary data

Journal Articles

Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2

Masato Terashima, Yosuke Togashi, Katsuaki Sato, Hiroshi Mizuuchi, Kazuko Sakai, Kenichi Suda, Yu Nakamura, Eri Banno, Hidetoshi Hayashi, Marco A. De Velasco, Yoshihiko Fujita, Shuta Tomida, Tetsuya Mitsudomi, Kazuto Nishio

Clin Cancer Res (2016) 22 (14): 3663–3671.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-2093

Published: 14 July 2016

View article

Includes: Supplementary data

Journal Articles

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

Yoshihisa Kobayashi, Yosuke Togashi, Yasushi Yatabe, Hiroshi Mizuuchi, Park Jangchul, Chiaki Kondo, Masaki Shimoji, Katsuaki Sato, Kenichi Suda, Kenji Tomizawa, Toshiki Takemoto, Toyoaki Hida, Kazuto Nishio, Tetsuya Mitsudomi

Clin Cancer Res (2015) 21 (23): 5305–5313.

DOI: https://doi.org/10.1158/1078-0432.CCR-15-1046

Published: 30 November 2015

View article

Includes: Supplementary data

Journal Articles

Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer

Clin Cancer Res (2015) 21 (23): 5245–5252.

DOI: https://doi.org/10.1158/1078-0432.CCR-14-3160

Published: 30 November 2015

View article

Journal Articles

Detection of Epidermal Growth Factor Receptor Mutations in Serum DNA Using the Scorpion ARMS in Patients with Advanced Non-Small-Cell Lung Cancer

Isamu Okamoto, Hideharu Kimura, Kazuo Kasahara, Kazuto Nishio

Clin Cancer Res (2007) 13 (19_Supplement): PL01-03.

Published: 15 August 2014

View article

Journal Articles

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Junko Tanizaki, Isamu Okamoto, Takafumi Okabe, Kazuko Sakai, Kaoru Tanaka, Hidetoshi Hayashi, Hiroyasu Kaneda, Ken Takezawa, Kiyoko Kuwata, Haruka Yamaguchi, Erina Hatashita, Kazuto Nishio, Kazuhiko Nakagawa

Clin Cancer Res (2012) 18 (22): 6219–6226.

DOI: https://doi.org/10.1158/1078-0432.CCR-12-0392

Published: 14 November 2012

View article

Includes: Supplementary data

Journal Articles

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

Kazuhiko Yamada, Noboru Yamamoto, Yasuhide Yamada, Hiroshi Nokihara, Yutaka Fujiwara, Taizo Hirata, Fumiaki Koizumi, Kazuto Nishio, Noriyuki Koyama, Tomohide Tamura

Clin Cancer Res (2011) 17 (8): 2528–2537.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-2638

Published: 14 April 2011

View article

Includes: Supplementary data

Journal Articles

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

Ken Takezawa, Isamu Okamoto, Kazuto Nishio, Pasi A. Jänne, Kazuhiko Nakagawa

Clin Cancer Res (2011) 17 (8): 2140–2148.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-2798

Published: 14 April 2011

View article

Includes: Supplementary data

Journal Articles

Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2⁺pTyr⁺ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo

Kanae Kudo, Tokuzo Arao, Kaoru Tanaka, Tomoyuki Nagai, Kazuyuki Furuta, Kazuko Sakai, Hiroyasu Kaneda, Kazuko Matsumoto, Daisuke Tamura, Keiichi Aomatsu, Marco A. De Velasco, Yoshihiko Fujita, Nagahiro Saijo, Masatoshi Kudo, Kazuto Nishio

Clin Cancer Res (2011) 17 (6): 1373–1381.

DOI: https://doi.org/10.1158/1078-0432.CCR-09-2755

Published: 15 March 2011

View article

Includes: Supplementary data

Journal Articles

Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma

Kazuo Kasahara, Tokuzo Arao, Kazuko Sakai, Kazuko Matsumoto, Asao Sakai, Hideharu Kimura, Takashi Sone, Atsushi Horiike, Makoto Nishio, Tatsuo Ohira, Norihiko Ikeda, Takeharu Yamanaka, Nagahiro Saijo, Kazuto Nishio

Clin Cancer Res (2010) 16 (18): 4616–4624.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-0383

Published: 14 September 2010

View article

Journal Articles

Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification

Takafumi Okabe, Isamu Okamoto, Sayaka Tsukioka, Junji Uchida, Erina Hatashita, Yuki Yamada, Takeshi Yoshida, Kazuto Nishio, Masahiro Fukuoka, Pasi A. Jänne, Kazuhiko Nakagawa

Clin Cancer Res (2009) 15 (3): 907–913.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-2251

Published: 02 February 2009

View article

Journal Articles

AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor

Masayuki Takeda, Tokuzo Arao, Hideyuki Yokote, Teruo Komatsu, Kazuyoshi Yanagihara, Hiroki Sasaki, Yasuhide Yamada, Tomohide Tamura, Kazuya Fukuoka, Hiroshi Kimura, Nagahiro Saijo, Kazuto Nishio

Clin Cancer Res (2007) 13 (10): 3051–3057.

DOI: https://doi.org/10.1158/1078-0432.CCR-06-2743

Published: 15 May 2007

View article

Journal Articles

Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer

Hideharu Kimura, Kazuo Kasahara, Makoto Kawaishi, Hideo Kunitoh, Tomohide Tamura, Brian Holloway, Kazuto Nishio

Clin Cancer Res (2006) 12 (13): 3915–3921.

DOI: https://doi.org/10.1158/1078-0432.CCR-05-2324

Published: 03 July 2006

View article

Journal Articles

Enhancement of Sensitivity to Tumor Necrosis Factor α in Non–Small Cell Lung Cancer Cells with Acquired Resistance to Gefitinib

Koichi Ando, Tohru Ohmori, Fumiko Inoue, Tsuyoki Kadofuku, Takamichi Hosaka, Hiroo Ishida, Takao Shirai, Kentaro Okuda, Takashi Hirose, Naoya Horichi, Kazuto Nishio, Nagahiro Saijo, Mitsuru Adachi, Toshio Kuroki

Clin Cancer Res (2005) 11 (24): 8872–8879.

DOI: https://doi.org/10.1158/1078-0432.CCR-05-0811

Published: 16 December 2005

View article

Journal Articles

In Vitro Synergistic Interactions between the Cisplatin Analogue Nedaplatin and the DNA Topoisomerase I Inhibitor Irinotecan and the Mechanism of this Interaction

Fumihiko Kanzawa, Fumiaki Koizumi, Yasuhiro Koh, Takashi Nakamura, Yasuaki Tatsumi, Hisao Fukumoto, Nagahiro Saijo, Takayuki Yoshioka, Kazuto Nishio

Clin Cancer Res (2001) 7 (1): 202–209.

Published: 01 January 2001

View article

NARROW

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

Correction: KRAS Inhibitor Resistance in MET-Amplified KRAS^G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

KRAS Inhibitor Resistance in MET-Amplified KRAS^G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer

Detection of Epidermal Growth Factor Receptor Mutations in Serum DNA Using the Scorpion ARMS in Patients with Advanced Non-Small-Cell Lung Cancer

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2⁺pTyr⁺ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo

Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma

Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification

AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor

Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer

Enhancement of Sensitivity to Tumor Necrosis Factor α in Non–Small Cell Lung Cancer Cells with Acquired Resistance to Gefitinib

In Vitro Synergistic Interactions between the Cisplatin Analogue Nedaplatin and the DNA Topoisomerase I Inhibitor Irinotecan and the Mechanism of this Interaction

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only